Get the Stockscreener App
35.00
1.77%
-0.63
Pre-market:
36.50
1.50
+4.29%
Tg Therapeutics Inc stock is traded at $35.00, with a volume of 1.70M.
It is down -1.77% in the last 24 hours and up +1.86% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$35.63
Open:
$35.06
24h Volume:
1.70M
Relative Volume:
0.66
Market Cap:
$6.26B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-318.18
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-11.24%
1M Performance:
+1.86%
6M Performance:
+4.26%
1Y Performance:
+111.23%
1-Day Range:
$34.55
$35.52
1-Week Range:
$34.55
$39.75
52-Week Range:
$16.39
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
35.00 | 6.26B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock - Nasdaq
Tg therapeutics director Yann Echelard sells $369,400 in stock - Investing.com Australia
(TGTX) Trading Advice - news.stocktradersdaily.com
Tg therapeutics director Yann Echelard sells $369,400 in stock By Investing.com - Investing.com Canada
TGTX Experiences Surge in Bullish Options Activity | TGTX Stock News - GuruFocus
Are Options Traders Betting on a Big Move in TG Therapeutics Stock? - TradingView
TG Therapeutics shareholders approve key proposals By Investing.com - Investing.com South Africa
TG Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
TG Therapeutics shareholders approve key proposals - Investing.com
TG Therapeutics at Goldman Sachs Conference: Strategic Growth and Innovations - Investing.com Canada
Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - marketscreener.com
GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | TGTX Stock News - GuruFocus
TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month - Yahoo
Kalkine: TG Therapeutics Schedules Fireside Chat at Goldman Sachs Conference Amid FT100 Futures Focus - Kalkine Media
TG Therapeutics CEO Fireside Chat at Goldman's Premier Healthcare Conference: Key Updates Coming - Stock Titan
Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
LAWSUITS FILED AGAINST U, TGTX and CVNAJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Transcript : TG Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 12 - marketscreener.com
(TGTX) Investment Analysis and Advice - news.stocktradersdaily.com
TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
TG Therapeutics CEO Fireside Chat: Key Updates Expected at Major Healthcare Conference - Stock Titan
TG Therapeutics shares MS drug trial updates By Investing.com - Investing.com South Africa
TG Therapeutics Announces Data Presentations for BRIUMVI in Mult - GuruFocus
TG Therapeutics shares MS drug trial updates - Investing.com
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting | TGTX Stock News - GuruFocus
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - The Manila Times
TG Therapeutics Highlights BRIUMVI® Data in Patients with Relapsing Forms of Multiple Sclerosis at CMSC 2025 Annual Meeting - Nasdaq
TG Therapeutics Announces Data Presentations for BRIUMVI in - GlobeNewswire
TG Therapeutics: Estimates Could Soon Be Raised Again (NASDAQ:TGTX) - Seeking Alpha
Man Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting | TGTX Stock News - GuruFocus
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting - The Manila Times
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at ... - Eagle-Tribune
Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
How To Trade (TGTX) - news.stocktradersdaily.com
Captrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial Markets - Defense World
TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture - simplywall.st
Investor Calendar Invites You to the TG Therapeutics, Inc. Third Quarter 2016 Earnings Conference Call and Webcast Live on Monday, November 7, 2016 - ACCESS Newswire
(TGTX) Long Term Investment Analysis - news.stocktradersdaily.com
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook - MSN
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):